{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:37:04Z","timestamp":1792705024892,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T00:00:00Z","timestamp":1413849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s12967-014-0291-1","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T19:01:52Z","timestamp":1413831712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014"],"prefix":"10.1186","volume":"12","author":[{"given":"Paolo A","family":"Ascierto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Carten\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Laurentis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Pietro","family":"Ianniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Montesarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,21]]},"reference":[{"key":"291_CR1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","volume":"1","author":"FM Burnet","year":"1957","unstructured":"Burnet FM: Cancer a biological approach. Br Med J. 1957, 1: 841-847. 10.1136\/bmj.1.5023.841.","journal-title":"Br Med J"},{"key":"291_CR2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD: Natural innate and adaptive immunity to cancer. Ann Rev Immunol. 2011, 29: 235-271. 10.1146\/annurev-immunol-031210-101324.","journal-title":"Ann Rev Immunol"},{"key":"291_CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003, 348: 203-213. 10.1056\/NEJMoa020177.","journal-title":"N Engl J Med"},{"key":"291_CR4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.bjc.6602934","volume":"94","author":"K Hiraoka","year":"2006","unstructured":"Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H: Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006, 94: 275-280. 10.1038\/sj.bjc.6602934.","journal-title":"Br J Cancer"},{"key":"291_CR5","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohou\u00e9 F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pag\u00e8s F: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313: 1960-1964. 10.1126\/science.1129139.","journal-title":"Science"},{"key":"291_CR6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C: Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02\u201398. J Clin Oncol. 2013, 31: 860-867. 10.1200\/JCO.2011.41.0902.","journal-title":"J Clin Oncol"},{"key":"291_CR7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-05-1886","volume":"12","author":"C Badoual","year":"2006","unstructured":"Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, Brasnu DF, Tartour E: Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006, 12: 465-472. 10.1158\/1078-0432.CCR-05-1886.","journal-title":"Clin Cancer Res"},{"key":"291_CR8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.bjc.6600437","volume":"87","author":"F Donskov","year":"2002","unstructured":"Donskov F, Bennedsgaard KM, Von Der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M: Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer. 2002, 87: 194-201. 10.1038\/sj.bjc.6600437.","journal-title":"Br J Cancer"},{"key":"291_CR9","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012, 30: 2678-2683. 10.1200\/JCO.2011.37.8539.","journal-title":"J Clin Oncol"},{"key":"291_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2011.06.002","volume":"75","author":"H Tao","year":"2012","unstructured":"Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H: Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012, 75: 95-101. 10.1016\/j.lungcan.2011.06.002.","journal-title":"Lung Cancer"},{"key":"291_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1479-5876-11-43","volume":"11","author":"A Mohos","year":"2013","unstructured":"Mohos A, Sebesty\u00e9n T, Liszkay G, Pl\u00f3t\u00e1r V, Horv\u00e1th S, Gaudi I, Lad\u00e1nyi A: Immune cell profile of sentinel lymph nodes in patients with malignant melanoma FOXP3+ cell density in metastatic sentinel nodes is associated with unfavourable clinical outcome. J Transl Med. 2013, 11: 43-54. 10.1186\/1479-5876-11-43.","journal-title":"J Transl Med"},{"key":"291_CR12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1593\/tlo.13256","volume":"6","author":"MJ Kang","year":"2013","unstructured":"Kang MJ, Kim KM, Bae JS, Park HS, Lee H, Chung MJ, Moon WS, Lee DG, Jang KY: Tumor-infiltrating PD1-positive lymphocytes and foxp3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol. 2013, 6: 282-289. 10.1593\/tlo.13256.","journal-title":"Transl Oncol"},{"key":"291_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013, 369: 122-133. 10.1056\/NEJMoa1302369.","journal-title":"N Engl J Med"},{"key":"291_CR14","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas A: Tumor immunotherapy directed at PD-1. N Engl J Med. 2012, 366: 2517-2519. 10.1056\/NEJMe1205943.","journal-title":"N Engl J Med"},{"key":"291_CR15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723. 10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"key":"291_CR16","volume-title":"Practical Management of Immune-Related Adverse Events from Immune Checkpoints Protein Antibodies for the Oncologists","author":"JS Weber","year":"2012","unstructured":"Weber JS: Practical Management of Immune-Related Adverse Events from Immune Checkpoints Protein Antibodies for the Oncologists. 2012, ASCO Educational Book."},{"key":"291_CR17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012, 366: 2443-2454. 10.1056\/NEJMoa1200690.","journal-title":"N Engl J Med"},{"issue":"5s","key":"291_CR18","doi-asserted-by":"crossref","first-page":"abstr 8112","DOI":"10.1200\/jco.2014.32.15_suppl.8112","volume":"32","author":"JM Brahmer","year":"2014","unstructured":"Brahmer JM, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Suk Heist R, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming PD, Topalian SL, Hodi FS, Sznol M, Harbison C, Kollia G, Gupta AK, Gettinger SN: Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 8112-","journal-title":"J Clin Oncol"},{"issue":"Supplement 2","key":"291_CR19","first-page":"abstract 880","volume":"49","author":"FS Hodi","year":"2013","unstructured":"Hodi FS, Topalian SL, Brahmer JR, McDermott DF, Smith DC, Gettinger S, Taube JM, Pardoll DM, Wigginton JM, Sznol M: Survival and long-term safety in patients (pts) with advanced solid tumors receiving nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. Eur J Cancer. 2013, 49 (Supplement 2): abstract 880-","journal-title":"Eur J Cancer"},{"key":"291_CR20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2013.00107","volume":"3","author":"TL Whiteside","year":"2013","unstructured":"Whiteside TL: Immune responses to cancer: are they potential biomarkers of prognosis?. Front Oncol. 2013, 3: 107-10.3389\/fonc.2013.00107.","journal-title":"Front Oncol"},{"issue":"Suppl 2","key":"291_CR21","first-page":"abstr P2.11-035","volume":"8","author":"SJ Antonia","year":"2013","unstructured":"Antonia SJ, Grosso JF, Horak CE, Harbison CT, Kurland JF, Inzunza HD, Gupta A, Sankar V, Park JS, Jure-Kunkel M, Novotny J, Cogswell J, Zhang X, Phillips T, Simmons P, Simon J: Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small cell lung cancer (NSCLC) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J Thorac Oncol. 2013, 8 (Suppl 2): abstr P2.11-035-","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"291_CR22","first-page":"abstr MO18.02","volume":"8","author":"EB Garon","year":"2013","unstructured":"Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N, Gubens MA, Goldman J, Lubiniecki GM, Lunceford J, Gergich K, Rizvi N: Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with NSCLC [abstract]. J Thorac Oncol. 2013, 8 (Suppl 2): abstr MO18.02-","journal-title":"J Thorac Oncol"},{"key":"291_CR23","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011, 364: 2517-2526. 10.1056\/NEJMoa1104621.","journal-title":"N Engl J Med"},{"key":"291_CR24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"A Di Giacomo","year":"2009","unstructured":"Di Giacomo A, Danielli R, Guidoboni M, Calabr\u00f2 L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009, 58: 1297-1306. 10.1007\/s00262-008-0642-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"16 suppl","key":"291_CR25","doi-asserted-by":"crossref","first-page":"abstract 8024","DOI":"10.1200\/jco.2014.32.15_suppl.8024","volume":"32","author":"SN Gettinger","year":"2014","unstructured":"Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Quan Man Chow L, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Rizvi NA: First-line nivolumab (anti PD1, BMS 936558) monotherapy in advanced NSCLC: safety, efficacy and correlation of outcomes with PD-L1 status [abstract]. J Clin Oncol. 2014, 32 (16 suppl): abstract 8024-","journal-title":"J Clin Oncol"},{"issue":"8S","key":"291_CR26","first-page":"abstract 13240","volume":"21","author":"C Lebb\u00e9","year":"2010","unstructured":"Lebb\u00e9 C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS: Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial [abstract]. Ann Oncol. 2010, 21 (8S): abstract 13240-","journal-title":"Ann Oncol"},{"key":"291_CR27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1479-5876-12-116","volume":"12","author":"PA Ascierto","year":"2014","unstructured":"Ascierto PA, Simeone E, Sileni VC, Pigozzo J, Maio M, Altomonte M, Del Vecchio M, Di Guardo L, Marchetti P, Ridolfi R, Cognetti F, Testori A, Bernengo MG, Guida M, Marconcini R, Mandal\u00e0 M, Cimminiello C, Rinaldi G, Aglietta M, Queirolo P: Clinical experience with ipilimumab 3 mg\/Kg: real-world efficacy and safety data from an expanded access programme cohort. J Translat Med. 2014, 12: 116-122. 10.1186\/1479-5876-12-116.","journal-title":"J Translat Med"},{"key":"291_CR28","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009, 15: 7412-7420. 10.1158\/1078-0432.CCR-09-1624.","journal-title":"Clin Cancer Res"},{"key":"291_CR29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2007.13.6259","volume":"26","author":"SJ O\u2019Day","year":"2008","unstructured":"O\u2019Day SJ, Ibrahim R, DePril V, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Hoos A, Humphrey R, Wolchock J: Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies [abstract 9021]. J Clin Oncol. 2008, 26: 18-10.1200\/JCO.2007.13.6259.","journal-title":"J Clin Oncol"},{"issue":"suppl. 15","key":"291_CR30","doi-asserted-by":"crossref","first-page":"abstract 9025","DOI":"10.1200\/jco.2008.26.15_suppl.9025","volume":"26","author":"O Hamid","year":"2008","unstructured":"Hamid O, Chin K, Li J, Neyns B, Linette G, Negrier S, Lutzky J, Hoos A, Wolchock J, Lebb\u00e9 C: Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study [abstract]. J Clin Oncol. 2008, 26 (suppl. 15): abstract 9025-","journal-title":"J Clin Oncol"},{"key":"291_CR31","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1158\/1078-0432.CCR-09-2376","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas A, Chmielowski B, Glaspy JA: Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin Cancer Res. 2009, 15: 7116-7118. 10.1158\/1078-0432.CCR-09-2376.","journal-title":"Clin Cancer Res"},{"key":"291_CR32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1078-0432.CCR-11-2323","volume":"18","author":"A Ribas","year":"2012","unstructured":"Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM: New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012, 18: 336-341. 10.1158\/1078-0432.CCR-11-2323.","journal-title":"Clin Cancer Res"},{"key":"291_CR33","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","volume":"30","author":"TJ Lynch","year":"2012","unstructured":"Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M: Ipilimumab in combination with carboplatin plus paclitaxel as first-line treatment in stage IIIB\/IV NSCLC: results from a randomised, double-blind, multicenter phase II study. J Clin Oncol. 2012, 30: 2046-2054. 10.1200\/JCO.2011.38.4032.","journal-title":"J Clin Oncol"},{"key":"291_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","volume":"24","author":"M Reck","year":"2013","unstructured":"Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ: Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013, 24: 75-83. 10.1093\/annonc\/mds213.","journal-title":"Ann Oncol"},{"issue":"15s","key":"291_CR35","doi-asserted-by":"crossref","first-page":"abstr 8071","DOI":"10.1200\/jco.2009.27.15_suppl.8071","volume":"27","author":"P Zatloukal","year":"2009","unstructured":"Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford D, Graziano S, Huang B, Healey D: Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2009, 27 (15s): abstr 8071-","journal-title":"J Clin Oncol"},{"issue":"5s","key":"291_CR36","doi-asserted-by":"crossref","first-page":"abstr 8023","DOI":"10.1200\/jco.2014.32.15_suppl.8023","volume":"32","author":"SJ Antonia","year":"2014","unstructured":"Antonia SJ, Gettinger S, Chow LQ, Juergens RA, Borghaei H, Shen Y, Harbison C, Chen AC, Ready N, Rizvi NA: Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 8023-","journal-title":"J Clin Oncol"},{"issue":"5s","key":"291_CR37","doi-asserted-by":"crossref","first-page":"abstr 8113","DOI":"10.1200\/jco.2014.32.15_suppl.8113","volume":"32","author":"SJ Antonia","year":"2014","unstructured":"Antonia SJ, Brahmer JR, Gettinger SN, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Gerber DE, Goldman JW, Shen Y, Harbison C, Alaparthy S, Chen AC, Borghaei H, Rizvi NA: Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 8113-","journal-title":"J Clin Oncol"},{"issue":"5s","key":"291_CR38","doi-asserted-by":"crossref","first-page":"abstr 8022","DOI":"10.1200\/jco.2014.32.15_suppl.8022","volume":"32","author":"NA Rizvi","year":"2014","unstructured":"Rizvi NA, Chow LQ, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Gettinger SN: Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 8022-","journal-title":"J Clin Oncol"},{"issue":"3s","key":"291_CR39","first-page":"abstr E17-7081","volume":"49","author":"G Giaccone","year":"2013","unstructured":"Giaccone G, Bazhenova L, Nemunaitis J, Juhasz E, Ramlau R, van den Heuvel MM, Lal R, Dunlop DJ, Carrier E, Fakhrai H: A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) [abstract]. Eur J Cancer. 2013, 49 (3s): abstr E17-7081-","journal-title":"Eur J Cancer"},{"key":"291_CR40","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2012.43.7103","volume":"31","author":"J Vansteenkiste","year":"2013","unstructured":"Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, Perdeus J, Bonnet R, Basko J, Janilionis R, Passlick B, Treasure T, Gillet M, Lehmann FF, Brichard VG: Adjuvant MAGE-A3 immunotherapy in resected NSCLC: phase II randomized study results. J Clin Oncol. 2013, 31: 2396-2403. 10.1200\/JCO.2012.43.7103.","journal-title":"J Clin Oncol"},{"issue":"Supplement 4","key":"291_CR41","first-page":"Abstract 1173","volume":"25","author":"JF Vansteenkiste","year":"2014","unstructured":"Vansteenkiste JF, Cho B, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Hondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Spiessens B, Brichard V, Debruyne C, Therasse P, Altorki N: MAGRIT, a double-blind, randomized, placebo-controlled phase III study to assess the efficacy of the recMAGE-A3 +AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC) [abstract]. Ann Oncol. 2014, 25 (Supplement 4): Abstract 1173-","journal-title":"Ann Oncol"},{"key":"291_CR42","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.1200\/JCO.2005.13.011","volume":"23","author":"C Butts","year":"2005","unstructured":"Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Souli\u00e8res D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M: Randomised phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV NSCLC. J Clin Oncol. 2005, 23: 6674-6681. 10.1200\/JCO.2005.13.011.","journal-title":"J Clin Oncol"},{"key":"291_CR43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosqu\u00e9e L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schr\u00f6der A, Shepherd FA: Tecemotide versus placebo after chemoradiotherapy for stage III NSCLC (START): a randomized, double-blind, phase III trial. Lancet Oncol. 2014, 15: 59-68. 10.1016\/S1470-2045(13)70510-2.","journal-title":"Lancet Oncol"},{"key":"291_CR44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fonc.2013.00128","volume":"3","author":"S Demaria","year":"2013","unstructured":"Demaria S, Formenti SC: Radiotherapy effects on antitumor immunity: implications for cancer treatment. Front Oncol. 2013, 3: 128-10.3389\/fonc.2013.00128.","journal-title":"Front Oncol"},{"key":"291_CR45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","volume":"12","author":"E Quoix","year":"2011","unstructured":"Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM: Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced NSCLC: a controlled phase IIB trial. Lancet Oncol. 2011, 12: 1125-1133. 10.1016\/S1470-2045(11)70259-5.","journal-title":"Lancet Oncol"},{"key":"291_CR46","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2007.14.7298","volume":"26","author":"E Neninger Vinageras","year":"2008","unstructured":"Neninger Vinageras E, de la Torre A, Osorio Rodr\u00edguez M, Catal\u00e1 Ferrer M, Bravo I, del Pino Mendoza M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, Gonz\u00e1lez Due\u00f1as M, Viada C, Garc\u00eda Verdecia B, Crombet Ramos T, Gonz\u00e1lez Marinello G, Lage D\u00e1vila A: Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced NSCLC. J Clin Oncol. 2008, 26: 3114-3121. 10.1200\/JCO.2007.14.7298.","journal-title":"J Clin Oncol"},{"key":"291_CR47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/107327481302000106","volume":"20","author":"PG Toomey","year":"2013","unstructured":"Toomey PG, Vohra NA, Ghansah T, Sarnaik AA, Pilon-Thomas SA: Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013, 20: 32-42.","journal-title":"Cancer Control"},{"key":"291_CR48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L: Inhibitory B7-family molecules in the tumour environment. Nature Rev Immunol. 2008, 8: 467-477. 10.1038\/nri2326.","journal-title":"Nature Rev Immunol"},{"key":"291_CR49","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA: Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010, 33: 828-833. 10.1097\/CJI.0b013e3181eec14c.","journal-title":"J Immunother"},{"key":"291_CR50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"key":"291_CR51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10: 25-34. 10.1016\/S1470-2045(08)70285-7.","journal-title":"Lancet Oncol"},{"key":"291_CR52","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","volume":"31","author":"JM Llovet","year":"2013","unstructured":"Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS Study. J Clin Oncol. 2013, 31: 3509-3516. 10.1200\/JCO.2012.47.3009.","journal-title":"J Clin Oncol"},{"key":"291_CR53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT: Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA. 2014, 312: 57-67. 10.1001\/jama.2014.7189.","journal-title":"JAMA"},{"key":"291_CR54","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009, 27: 740-745. 10.1200\/JCO.2008.16.3055.","journal-title":"J Clin Oncol"},{"key":"291_CR55","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007, 25: 4722-4729. 10.1200\/JCO.2007.12.2440.","journal-title":"J Clin Oncol"},{"key":"291_CR56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","volume":"28","author":"OL Chinot","year":"2011","unstructured":"Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T: AVAGLIO: phase III trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011, 28: 334-340. 10.1007\/s12325-011-0007-3.","journal-title":"Adv Ther"},{"key":"291_CR57","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014, 370: 699-708. 10.1056\/NEJMoa1308573.","journal-title":"N Engl J Med"},{"key":"291_CR58","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-04-1737","volume":"11","author":"AB Heimberger","year":"2005","unstructured":"Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K: Prognostic effect of EGFR and EGFR vIII in glioblastoma multiforme patients. Clin Cancer Res. 2005, 11: 1462-1466. 10.1158\/1078-0432.CCR-04-1737.","journal-title":"Clin Cancer Res"},{"key":"291_CR59","first-page":"93","volume":"7","author":"R Babu","year":"2012","unstructured":"Babu R, Adamson DC: Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFR vIII-positive glioblastoma. Core Evid. 2012, 7: 93-103.","journal-title":"Core Evid"},{"key":"291_CR60","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"31","author":"JH Sampson","year":"2010","unstructured":"Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD: Immunologic escape after prolonged progression-free survival with EGFR variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010, 31: 4722-4729. 10.1200\/JCO.2010.28.6963.","journal-title":"J Clin Oncol"},{"key":"291_CR61","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1111\/j.1582-4934.2009.00911.x","volume":"14","author":"C Napoletano","year":"2010","unstructured":"Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V, Sale P, Liberati M, Rughetti A, Frati L, Panici PB, Nuti M: Ovarian cancer cytoreduction induces changes in T-cell population subsets reducing immunosuppression. J Cell Mol Med. 2010, 14: 2748-2759. 10.1111\/j.1582-4934.2009.00911.x.","journal-title":"J Cell Mol Med"},{"key":"291_CR62","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.1073\/pnas.0703342104","volume":"104","author":"K Odunsi","year":"2007","unstructured":"Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S: Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007, 104: 12837-12842. 10.1073\/pnas.0703342104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"291_CR63","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1078-0432.CCR-03-0056","volume":"10","author":"S Reinartz","year":"2004","unstructured":"Reinartz S, K\u00f6hler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, M\u00f6bus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA 125: immunological response and survival (phase IB\/II). Clin Cancer Res. 2004, 10: 1580-1587. 10.1158\/1078-0432.CCR-03-0056.","journal-title":"Clin Cancer Res"},{"key":"291_CR64","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","volume":"31","author":"P Sabbatini","year":"2013","unstructured":"Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J: Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO, the MIMOSA trial. J Clin Oncol. 2013, 31: 1554-1561. 10.1200\/JCO.2012.46.4057.","journal-title":"J Clin Oncol"},{"key":"291_CR65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","volume":"27","author":"J Berek","year":"2009","unstructured":"Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF: Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009, 27: 418-425. 10.1200\/JCO.2008.17.8400.","journal-title":"J Clin Oncol"},{"key":"291_CR66","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, J\u00e4ger M, Str\u00f6hlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I\/II study. Clin Cancer Res. 2007, 13: 3899-3905. 10.1158\/1078-0432.CCR-06-2769.","journal-title":"Clin Cancer Res"},{"key":"291_CR67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/0008-5472.CAN-11-2235","volume":"72","author":"M J\u00e4ger","year":"2012","unstructured":"J\u00e4ger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Str\u00f6hlein M, Theissen B, Heiss MM, Lindhofer H: Immuno-monitoring results of a phase II\/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res. 2012, 72: 24-32. 10.1158\/0008-5472.CAN-11-2235.","journal-title":"Cancer Res"},{"key":"291_CR68","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1479-5876-5-66","volume":"5","author":"R Lenzi","year":"2007","unstructured":"Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS: Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med. 2007, 5: 66-70. 10.1186\/1479-5876-5-66.","journal-title":"J Transl Med"},{"key":"291_CR69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fimmu.2013.00192","volume":"4","author":"KM Hargadon","year":"2013","unstructured":"Hargadon KM: Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol. 2013, 4: 192-196. 10.3389\/fimmu.2013.00192.","journal-title":"Front Immunol"},{"key":"291_CR70","first-page":"1331","volume":"6","author":"MA Morse","year":"1999","unstructured":"Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK: A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous humen cultured dendritic cells in patients with metastatic malignancies expressing carinoembryonic antigen. Clin Cancer Res. 1999, 6: 1331-1338.","journal-title":"Clin Cancer Res"},{"key":"291_CR71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-001-0255-1","volume":"51","author":"JJ Hernando","year":"2002","unstructured":"Hernando JJ, Park TW, K\u00fcbler K, Offergeld R, Schlebusch H, Bauknecht T: Vaccination with autologous tumor antigen-pulsed dendritic cells in advanced gynecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother. 2002, 51: 45-52. 10.1007\/s00262-001-0255-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"5s","key":"291_CR72","doi-asserted-by":"crossref","first-page":"abstr 5511","DOI":"10.1200\/jco.2014.32.15_suppl.5511","volume":"32","author":"J Hamanishi","year":"2014","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Kanai M, Mori Y, Matsumoto S, Murayama T, Chikuma S, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I: Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 5511-","journal-title":"J Clin Oncol"},{"key":"291_CR73","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.10372","volume":"94","author":"RS Herbst","year":"2002","unstructured":"Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002, 94: 1593-1611. 10.1002\/cncr.10372.","journal-title":"Cancer"},{"key":"291_CR74","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008, 359: 1116-1127. 10.1056\/NEJMoa0802656.","journal-title":"N Engl J Med"},{"key":"291_CR75","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/annonc\/mdq588","volume":"22","author":"L Licitra","year":"2011","unstructured":"Licitra L, Mesia R, Rivera F, Remen\u00e1r E, Hitt R, Erf\u00e1n J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, St\u00f6rkel S, Senger S, Stroh C, Vermorken JB: Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and\/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011, 22: 1078-1087. 10.1093\/annonc\/mdq588.","journal-title":"Ann Oncol"},{"key":"291_CR76","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","volume":"14","author":"JB Vermorken","year":"2013","unstructured":"Vermorken JB, St\u00f6hlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA: Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013, 14: 697-710. 10.1016\/S1470-2045(13)70181-5.","journal-title":"Lancet Oncol"},{"key":"291_CR77","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","volume":"73","author":"S Lyford-Pike","year":"2013","unstructured":"Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, Pardoll DM, Pai SI: Evidence for a role of the PD1\/PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013, 73: 1733-1741. 10.1158\/0008-5472.CAN-12-2384.","journal-title":"Cancer Res"},{"key":"291_CR78","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1200\/JCO.2009.26.3483","volume":"28","author":"EJ Small","year":"2010","unstructured":"Small EJ, Fong M: Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010, 28: 1085-1087. 10.1200\/JCO.2009.26.3483.","journal-title":"J Clin Oncol"},{"key":"291_CR79","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010, 363: 411-422. 10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med"},{"key":"291_CR80","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","volume":"24","author":"EJ Small","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006, 24: 3089-3094. 10.1200\/JCO.2005.04.5252.","journal-title":"J Clin Oncol"},{"key":"291_CR81","first-page":"3689","volume":"61","author":"JP Machiels","year":"2001","unstructured":"Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM: Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of GM-CSF-secreting whole cell vaccines in HER-2-neu tolerized mice. Cancer Res. 2001, 61: 3689-3697.","journal-title":"Cancer Res"},{"key":"291_CR82","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2009.22.2299","volume":"27","author":"CG Drake","year":"2009","unstructured":"Drake CG: Immunotherapy for prostate cancer: walk, don\u2019t run. J Clin Oncol. 2009, 27: 4035-4037. 10.1200\/JCO.2009.22.2299.","journal-title":"J Clin Oncol"},{"key":"291_CR83","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengel\u00f8v L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR: Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014, 15: 700-712. 10.1016\/S1470-2045(14)70189-5.","journal-title":"Lancet Oncol"},{"issue":"4s","key":"291_CR84","doi-asserted-by":"crossref","first-page":"abstr 2","DOI":"10.1200\/jco.2014.32.4_suppl.2","volume":"32","author":"CG Drake","year":"2014","unstructured":"Drake CG, Kwon ED, Fizazi K, Bossi A, van den Eertwegh AJM, Logothetis C, Scher HI, Beer TM, McHenry B, Liu D, Gerritsen WR: Results of subset analyses on overall survival (OS) from study CA184-043: ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2014, 32 (4s): abstr 2-","journal-title":"J Clin Oncol"},{"key":"291_CR85","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010, 28: 1099-1105. 10.1200\/JCO.2009.25.0597.","journal-title":"J Clin Oncol"},{"key":"291_CR86","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","volume":"21","author":"S Halabi","year":"2003","unstructured":"Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003, 21: 1232-1237. 10.1200\/JCO.2003.06.100.","journal-title":"J Clin Oncol"},{"key":"291_CR87","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","volume":"16","author":"BC Carthon","year":"2010","unstructured":"Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P: Pre-operative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial. Clin Cancer Res. 2010, 16: 2861-2871. 10.1158\/1078-0432.CCR-10-0569.","journal-title":"Clin Cancer Res"},{"issue":"5s","key":"291_CR88","doi-asserted-by":"crossref","first-page":"abstr 5011","DOI":"10.1200\/jco.2014.32.15_suppl.5011","volume":"32","author":"T Powles","year":"2014","unstructured":"Powles T, Vogelzang NJ, Fine GD, Eder JP, Braiteh FS, Loriot Y, Cruz Zambrano C, Bellmunt J, Burris HA, Teng MS, Shen X, Koeppen H, Hegde PS, Chen DS, Petrylak DP: Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 5011-","journal-title":"J Clin Oncol"},{"key":"291_CR89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","volume":"113","author":"JA Klapper","year":"2008","unstructured":"Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S: High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006. Cancer. 2008, 113: 293-301. 10.1002\/cncr.23552.","journal-title":"Cancer"},{"key":"291_CR90","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/cncr.21470","volume":"104","author":"RH Thompson","year":"2005","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC, Kwon ED: Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005, 104: 2084-2091. 10.1002\/cncr.21470.","journal-title":"Cancer"},{"issue":"5s","key":"291_CR91","doi-asserted-by":"crossref","first-page":"abstr 4504","DOI":"10.1200\/jco.2014.32.15_suppl.4504","volume":"32","author":"HJ Hammers","year":"2014","unstructured":"Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Razak ARA, Pal SK, Voss M, Sharma P, Kollmannsberger CK, Chin Heng DY, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Amin A: Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma [abstract]. J Clin Oncol. 2014, 32 (5s): abstr 4504-","journal-title":"J Clin Oncol"},{"key":"291_CR92","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","volume":"30","author":"JC Yang","year":"2007","unstructured":"Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA: Ipilimumab causes regression of metastatic renal cell carcinoma associated with enteritis and hypophysitis. J Immunother. 2007, 30: 825-830. 10.1097\/CJI.0b013e318156e47e.","journal-title":"J Immunother"},{"key":"291_CR93","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor FOXP3. Science. 2003, 299: 1057-1061. 10.1126\/science.1079490.","journal-title":"Science"},{"key":"291_CR94","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002, 169: 2756-2761. 10.4049\/jimmunol.169.5.2756.","journal-title":"J Immunol"},{"key":"291_CR95","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2008.17.9036","volume":"27","author":"A Merlo","year":"2009","unstructured":"Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, M\u00e8nard S, Tagliabue E, Balsari A: FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009, 27: 1746-1752. 10.1200\/JCO.2008.17.9036.","journal-title":"J Clin Oncol"},{"key":"291_CR96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2407-8-57","volume":"8","author":"H Ghebeh","year":"2008","unstructured":"Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S: FOXP3+ Tregs and B7 H1+\/PD 1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer. 2008, 8: 57-10.1186\/1471-2407-8-57.","journal-title":"BMC Cancer"},{"key":"291_CR97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1593\/neo.05733","volume":"8","author":"H Ghebeh","year":"2006","unstructured":"Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, Ajarim D, Al-Tweigeri T, Dermime S: The B7 H1 (PD L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006, 8: 190-198. 10.1593\/neo.05733.","journal-title":"Neoplasia"},{"key":"291_CR98","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","volume":"108","author":"J Stagg","year":"2011","unstructured":"Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ: Anti ErbB 2 mAb therapy requires type I and II interferons and synergizes with anti PD 1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011, 108: 7142-7147. 10.1073\/pnas.1016569108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 2","key":"291_CR99","first-page":"24LBA","volume":"49","author":"D Schadendorf","year":"2013","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Chen TT, Berman DM, Wolchok JD: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract]. Eur J Cancer. 2013, 49 (suppl 2): 24LBA-","journal-title":"Eur J Cancer"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-014-0291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-014-0291-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-014-0291-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T23:57:05Z","timestamp":1598399825000},"score":1,"resource":{"primary":{"URL":"http:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-014-0291-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,21]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1186\/s12967-014-0291-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,21]]},"article-number":"291"}}